The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2022 | Treatment approaches for transplant-eligible and transplant-ineligbile myeloma patients
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses treatment approaches for transplant-eligible and transplant-ineligible myeloma patients and the benefit of these combination therapies. Dr Ramasamy discusses the option of quadruplet therapy with daratumumab, bortezomib, thalidomide, and dexamethasone (D-VTd) for transplant-eligible patients, and lenalidomide plus dexamethasone or bortezomib-based regimens for transplant-ineligible patients. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
